News in the drug treatment of metastatic uveal melanoma

    Abstract

    Original article

    News in the drug treatment of metastatic uveal melanoma

    V.V. Nazarova, K.V. Orlova, Z.R. Magomedova, L.V. Demidov

    N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation

    Purpos. To present promising research in the treatment of patients with metastatic uveal melanoma.

    Material and methods. The literature review included published full-text articles, as well as abstracts and thesis on the results of clinical trials that were presented at major oncological congresses (ESMO and ASCO) for the period from 2023 to 2025.

    Results. This review presents options for available drug alternatives for patients with metastatic uveal melanoma, indicating efficiency data. The results of clinical studies on the use of potentially new targeted and immunological molecules and combinations of treatment methods presented at international oncological congresses are described in detail.

    Conclusion. New research makes it possible to expect a change in the fatal prognosis in the treatment of metastatic uveal melanoma.

    Key words: uveal melanoma, metastatic uveal melanoma, targeted therapy, tebentafusp, immunotherapy

    For citation: Nazarova V.V., Orlova K.V., Magomedova Z.R., Demidov L.V. News in the drug treatment of metastatic uveal melanoma. Fyodorov Journal of Ophthalmic Surgery. 2025;2s(145): 94–100.

    DOI: 10.25276/0235-4160-2025-2S-94-100

    Corresponding author: Valeriya V. Nazarova, jezerovel@gmail.com